Friday, July 10, 2026

pharma · Breast Cancer · Multiple Sclerosis (MS)

HOFFMANN-LA ROCHE

Hoffmann-La Roche is a pharma organization headquartered in Basel, CH. Primary therapeutic focus areas include Breast Cancer, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), Non-Small Cell Lung Cancer, Solid Tumo

Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mississauga, Ontario L5N 5M8, CA
Employees
10
Programs
286
Drugs
212
Patents
0
Clinical program

WN42086

Phase 3 · small molecule · Relapsing-Remitting Multiple Sclerosis

WN42086 for Relapsing-Remitting Multiple Sclerosis is a Phase 3 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).

← All Hoffmann-La Roche projects Phase 3 small molecule active

Internal code WN42086

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Hoffmann-La Roche
Phase
Phase 3
Modality
small_molecule
Indication
Relapsing-Remitting Multiple Sclerosis
Status
active
Trials
1